Beclomethasone dipropionate in microscopic colitis: Results of an exploratory open‐label multicentre study (COLCO). Issue 9 (1st November 2019)

• Record Type: Journal Article
• Authors: De Corte, Thomas; Janssens, Emilie; D'Hondt, Ann; Thorrez, Koen; Arts, Joris; Dejaegher, Katrien; D'Heygere, François; Holvoet, Annelies; van Besien, Bart; Harlet, Luc; Peeters, Harald; Van Moerkercke, Wouter; Baert, Filip
• Is Part Of: United European Gastroenterology journal. Volume 7:Issue 9(2019)
• Page Start: 1183
• Page End: 1188
• Publication Date: 2019-11-01
• Subjects: IBD -- microscopic colitis -- lymphocytic colitis -- collagenous colitis -- beclomethasone dipropionate -- budesonide; Gastroenterology -- Periodicals; Periodicals; 616.33005
• DOI: 10.1177/2050640619860965
• Languages: English
• ISSNs: 2050-6406

Abstract

Abstract : Background: Budesonide has been proven to be an effective treatment for microscopic colitis (MC). However, the two current commercially available preparations are released in the ileum. Beclomethasone dipropionate (Clipper®) is a synthetic corticosteroid with topical colonic release. Objective: This study aimed to explore whether an open‐label treatment with beclomethasone dipropionate is an effective treatment for MC. Methods: Prospectively collected data of 30 patients from six centres were retrospectively analysed. All patients had a confirmed diagnosis of idiopathic MC (lymphocytic and collagenous colitis) and were symptomatic (i.e. ≥ 21 loose stools over a seven‐day period). Treatment consisted of 10 mg beclomethasone daily for four weeks, followed by 5 mg daily for another four weeks. The primary end point was the proportion of patients in remission (i.e. a mean of < 3 stools/day and a mean of <1 watery stool per day) after an eight‐week treatment period. Secondary end points were the proportion of patients responding to therapy at weeks 4 and 8, remission at weeks 4 and 12 and relapse at week 12. Reported adverse events were collected. Results: Overall, at week 8, remission was achieved in 70%, and 77% of patients were responding to treatment. After four weeks of treatment, 80% were responding, and 67% were in remission. Four weeks after stopping treatment, 60% were still in remission. Conclusion: This open‐label study suggests that an eight‐week course of beclomethasone could be a promising and relatively safe treatment for MC. A randomised controlled study is warranted.